Limits...
Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.

Linhart B, Narayanan M, Focke-Tejkl M, Wrba F, Vrtala S, Valenta R - Clin. Exp. Allergy (2014)

Bottom Line: The effects of peptide-specific and allergen-specific antibodies on T cell responses and allergic lung inflammation were studied using specific antibodies.Prophylactic and therapeutic vaccination of mice with the peptide vaccine induced Bet v 1-specific antibodies which suppressed Bet v 1-specific T cell responses and allergic lung inflammation.Vaccination with carrier-bound allergen-derived peptides lacking allergen-specific T cell epitopes induces allergen-specific IgG antibodies which suppress allergen-specific T cell responses and allergic lung inflammation.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Show MeSH
T cell responses of mice from the therapeutic scheme. Bet v 1- (a), peptide- (b), and KLH-specific (c) proliferations of splenocytes from mice of the therapeutic scheme (Fig.2) are displayed (y-axes: stimulation indices SI ± SD). Statistically significant differences are indicated (*P < 0.05). S: sensitization, T: therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215111&req=5

fig06: T cell responses of mice from the therapeutic scheme. Bet v 1- (a), peptide- (b), and KLH-specific (c) proliferations of splenocytes from mice of the therapeutic scheme (Fig.2) are displayed (y-axes: stimulation indices SI ± SD). Statistically significant differences are indicated (*P < 0.05). S: sensitization, T: therapy.

Mentions: We furthermore tested the ability of the peptide vaccine to affect an already established allergen-specific T cell response in our mouse model. We found that after sensitization to Bet v 1, a robust Bet v 1-specific T cell response (i.e. SI's >10) was established (Fig.6a, S+/T−). This response was significantly reduced when mice were treated with the peptide vaccine (Fig.6a, S+/T+; P < 0.05). A relevant peptide-specific proliferation was observed in none of the mouse groups (Fig.6b). Mice treated with the peptide vaccine, but not mice who had not received the peptide vaccine, showed carrier-specific T cell responses (Fig.6c).


Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.

Linhart B, Narayanan M, Focke-Tejkl M, Wrba F, Vrtala S, Valenta R - Clin. Exp. Allergy (2014)

T cell responses of mice from the therapeutic scheme. Bet v 1- (a), peptide- (b), and KLH-specific (c) proliferations of splenocytes from mice of the therapeutic scheme (Fig.2) are displayed (y-axes: stimulation indices SI ± SD). Statistically significant differences are indicated (*P < 0.05). S: sensitization, T: therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215111&req=5

fig06: T cell responses of mice from the therapeutic scheme. Bet v 1- (a), peptide- (b), and KLH-specific (c) proliferations of splenocytes from mice of the therapeutic scheme (Fig.2) are displayed (y-axes: stimulation indices SI ± SD). Statistically significant differences are indicated (*P < 0.05). S: sensitization, T: therapy.
Mentions: We furthermore tested the ability of the peptide vaccine to affect an already established allergen-specific T cell response in our mouse model. We found that after sensitization to Bet v 1, a robust Bet v 1-specific T cell response (i.e. SI's >10) was established (Fig.6a, S+/T−). This response was significantly reduced when mice were treated with the peptide vaccine (Fig.6a, S+/T+; P < 0.05). A relevant peptide-specific proliferation was observed in none of the mouse groups (Fig.6b). Mice treated with the peptide vaccine, but not mice who had not received the peptide vaccine, showed carrier-specific T cell responses (Fig.6c).

Bottom Line: The effects of peptide-specific and allergen-specific antibodies on T cell responses and allergic lung inflammation were studied using specific antibodies.Prophylactic and therapeutic vaccination of mice with the peptide vaccine induced Bet v 1-specific antibodies which suppressed Bet v 1-specific T cell responses and allergic lung inflammation.Vaccination with carrier-bound allergen-derived peptides lacking allergen-specific T cell epitopes induces allergen-specific IgG antibodies which suppress allergen-specific T cell responses and allergic lung inflammation.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Show MeSH